CXCR3 modulates glial accumulation and activation in cuprizone-induced demyelination of the central nervous system

Journal of Neuroinflammation

Volumn 11, Issue , 2014, Pages

  Krauthausen, Marius ^a   Saxe, Simon ^a   Zimmermann, Julian ^a   Emrich, Michael ^a   Heneka, Michael T ^a   Müller, Marcus ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

CNS inflammation; cuprizone model; CXCR3 signaling; CXCR3 ; microglia

Indexed keywords

CD11B ANTIGEN; CD45 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; CUPRIZONE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLIAL FIBRILLARY ACIDIC PROTEIN; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR; CXCR3 PROTEIN, MOUSE; CYTOKINE; LEUKOCYTE ANTIGEN; MESSENGER RNA; MONOAMINE OXIDASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BIOACCUMULATION; BODY WEIGHT; CELL ACTIVATION; CELL COUNT; CELLULAR DISTRIBUTION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DEMYELINATION; DISEASE COURSE; ENZYME ACTIVATION; GLIA CELL; IMMUNOHISTOCHEMISTRY; MICROGLIA; MORPHOMETRICS; MOUSE; NERVOUS SYSTEM INFLAMMATION; NEUROMODULATION; NONHUMAN; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; ANALYSIS OF VARIANCE; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; DEFICIENCY; DEMYELINATING DISEASE; DRUG EFFECTS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; GLIA; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE;

ANALYSIS OF VARIANCE; ANIMALS; ANTIGENS, CD; BODY WEIGHT; CUPRIZONE; CYTOKINES; DEMYELINATING DISEASES; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MONOAMINE OXIDASE INHIBITORS; NEUROGLIA; RECEPTORS, CXCR3; RNA, MESSENGER;

EID: 84904131964     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-11-109     Document Type: Article

References (69)

1. Nedergaard M, Ransom B, Goldman SA. New roles for astrocytes: Redefining the functional architecture of the brain. Trends Neurosci 2003, 26:523-530.
2. Perea G, Navarrete M, Araque A. Tripartite synapses: astrocytes process and control synaptic information. Trends Neurosci 2009, 32:421.
3. Obara M, Szeliga M, Albrecht J. Regulation of pH in the mammalian central nervous system under normal and pathological conditions: facts and hypotheses. Neurochem Int 2008, 52:905-919.
4. Simard M, Nedergaard M. The neurobiology of glia in the context of water and ion homeostasis. Neuroscience 2004, 129:877-896.
5. Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol 2010, 119:7-35.
6. Tremblay M-T, Stevens B, Sierra A, Wake H, Bessis A, Nimmerjahn A. The role of microglia in the healthy brain. J Neurosci 2011, 31:16064-16069.
7. Farina C, Aloisi F, Meinl E. Astrocytes are active players in cerebral innate immunity. Trends Immunol 2007, 28:138-145.
8. Dong Y, Benveniste EN. Immune function of astrocytes. Glia 2001, 36:180-190.
9. Cao L, He C. Polarization of macrophages and microglia in inflammatory demyelination. Neurosci Bull 2013, 29:189-198.
10. Ransohoff RM, Perry VH. Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol 2009, 27:119-145.
11. Gasque P, Dean YD, McGreal EP, VanBeek J, Morgan BP. Complement components of the innate immune system in health and disease in the CNS. Immunopharmacol 2000, 49:171-186.
12. Bowman CC, Rasley A, Tranguch SL, Marriott I. Cultured astrocytes express toll-like receptors for bacterial products. Glia 2003, 43:281-291.
13. Carpentier PA, Begolka WS, Olson JK, Elhofy A, Karpus WJ, Miller SD. Differential activation of astrocytes by innate and adaptive immune stimuli. Glia 2005, 49:360-374.
14. Aloisi F. Immune function of microglia. Glia 2001, 36:165-179.
15. Olson JK, Miller SD. Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J Immunol 2004, 173:3916-3924.
16. Husemann J, Loike JD, Anankov R, Febbraio M, Silverstein SC. Scavenger receptors in neurobiology and neuropathology: their role on microglia and other cells of the nervous system. Glia 2002, 40:195-205.
17. Van Weering HRJ, Boddeke HWGM, Vinet J, Brouwer N, de Haas AH, van Rooijen N, Thomsen AR, Biber KPH. CXCL10/CXCR3 signaling in glia cells differentially affects NMDA-induced cell death in CA and DG neurons of the mouse hippocampus. Hippocampus 2011, 21:220-232.
18. Amin DN, Rottenberg ME, Thomsen AR, Mumba D, Fenger C, Kristensson K, Büscher P, Finsen B, Masocha W. Expression and role of CXCL10 during the encephalitic stage of experimental and clinical African trypanosomiasis. J Infect Dis 2009, 200:1556-1565.
19. Hofer MJ, Carter SL, Müller M, Campbell IL. Unaltered neurological disease and mortality in CXCR3-deficient mice infected intracranially with lymphocytic choriomeningitis virus-Armstrong. Viral Immunol 2008, 21:425-433.
20. Müller M, Carter SL, Hofer MJ, Manders P, Getts DR, Getts MT, Dreykluft A, Lu B, Gerard C, King NJC, Campbell IL. CXCR3 signaling reduces the severity of experimental autoimmune encephalomyelitis by controlling the parenchymal distribution of effector and regulatory T cells in the central nervous system. J Immunol 2007, 179:2774-2786.
21. Klein RS, Lin E, Zhang B, Luster AD, Tollett J, Samuel MA, Engle M, Diamond MS. Neuronal CXCL10 directs CD8+ T-cell recruitment and control of West Nile virus encephalitis. J Virol 2005, 79:11457-11466.
22. Tsunoda I, Lane TE, Blackett J, Fujinami RS. Distinct roles for IP-10/CXCL10 in three animal models, Theiler's virus infection, EAE, and MHV infection, for multiple sclerosis: implication of differing roles for IP-10. Mult Scler 2004, 10:26-34.
23. Rappert A, Bechmann I, Pivneva T, Mahlo J, Biber K, Nolte C, Kovac AD, Gerard C, Boddeke HWGM, Nitsch R, Kettenmann H. CXCR3-dependent microglial recruitment is essential for dendrite loss after brain lesion. J Neurosci 2004, 24:8500-8509.
24. Rupprecht TA, Koedel U, Muhlberger B, Wilske B, Fontana A, Pfister H-W. CXCL11 is involved in leucocyte recruitment to the central nervous system in neuroborreliosis. J Neurol 2005, 252:820-823.
25. Stiles LN, Hardison JL, Schaumburg CS, Whitman LM, Lane TE. T cell antiviral effector function is not dependent on CXCL10 following murine coronavirus infection. J Immunol 2006, 177:8372-8380.
26. Campanella GSV, Tager AM, El Khoury JK, Thomas SY, Abrazinski TA, Manice LA, Colvin RA, Luster AD. Chemokine receptor CXCR3 and its ligands CXCL9 and CXCL10 are required for the development of murine cerebral malaria. Proc Natl Acad Sci U S A 2008, 105:4814-4819.
27. Luster AD, Unkeless JC, Ravetch JV. Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature 1985, 315:672-676.
28. Cole KE, Strick CA, Paradis TJ, Ogborne KT, Loetscher M, Gladue RP, Lin W, Boyd JG, Moser B, Wood DE, Sahagan BG, Neote K. Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 1998, 187:2009-2021.
29. Choi K, Ni L, Jonakait GM. Fas ligation and tumor necrosis factor alpha activation of murine astrocytes promote heat shock factor-1 activation and heat shock protein expression leading to chemokine induction and cell survival. J Neurochem 2011, 116:438-448.
30. Carter SL, Müller M, Manders PM, Campbell IL. Induction of the genes for Cxcl9 and Cxcl10 is dependent on IFN-gamma but shows differential cellular expression in experimental autoimmune encephalomyelitis and by astrocytes and microglia in vitro. Glia 2007, 55:1728-1739.
31. Loetscher M, Loetscher P, Brass N, Meese E, Moser B. Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization. Eur J Immunol 1998, 28:3696-3705.
32. Weng Y, Siciliano SJ, Waldburger KE, Sirotina-Meisher A, Staruch MJ, Daugherty BL, Gould SL, Springer MS, DeMartino JA. Binding and functional properties of recombinant and endogenous CXCR3 chemokine receptors. J Biol Chem 1998, 273:18288-18291.
33. Proost P, Schutyser E, Menten P, Struyf S, Wuyts A, Opdenakker G, Detheux M, Parmentier M, Durinx C, Lambeir A-M, Neyts J, Liekens S, Maudgal PC, Billiau A, Van Damme J. Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. Blood 2001, 98:3554-3561.
34. Colvin RA, Campanella GSV, Sun J, Luster AD. Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function. J Biol Chem 2004, 279:30219-30227.
35. Colvin RA, Campanella GSV, Manice LA, Luster AD. CXCR3 requires tyrosine sulfation for ligand binding and a second extracellular loop arginine residue for ligand-induced chemotaxis. Mol Cell Biol 2006, 26:5838-5849.
36. Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J, Dzuiba J, Van Damme J, Walz A, Marriott D. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 1995, 270:27348-27357.
37. Strieter RM, Burdick MD, Gomperts BN, Belperio JA, Keane MP. CXC chemokines in angiogenesis. Cytokine Growth Factor Rev 2005, 16:593-609.
38. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000, 12:121-127.
39. Bonacchi A, Romagnani P, Romanelli RG, Efsen E, Annunziato F, Lasagni L, Francalanci M, Serio M, Laffi G, Pinzani M, Gentilini P, Marra F. Signal transduction by the chemokine receptor CXCR3: activation of Ras/ERK, Src, and phosphatidylinositol 3-kinase/Akt controls cell migration and proliferation in human vascular pericytes. J Biol Chem 2001, 276:9945-9954.
40. Kim TS, Kang BY, Lee MH, Choe YK, Hwang SY. Inhibition of interleukin-12 production by auranofin, an anti-rheumatic gold compound, deviates CD4(+) T cells from the Th1 to the Th2 pathway. Br J Pharmacol 2001, 134:571-578.
41. Biber K, Dijkstra I, Trebst C, De Groot CJA, Ransohoff RM, Boddeke H. Functional expression of CXCR3 in cultured mouse and human astrocytes and microglia. Neuroscience 2002, 112:487-497.
42. De Jong EK, de Haas AH, Brouwer N, van Weering HRJ, Hensens M, Bechmann I, Pratley P, Wesseling E, Boddeke HWGM, Biber K. Expression of CXCL4 in microglia in vitro and in vivo and its possible signaling through CXCR3. J Neurochem 2008, 105:1726-1736.
43. Flynn G. Regulation of chemokine receptor expression in human microglia and astrocytes. J Neuroimmunol 2003, 136:84-93.
44. Lepej SZ, Rode OD, Jeren T, Vince A, Remenar A, Barsić B. Increased expression of CXCR3 and CCR5 on memory CD4+ T-cells migrating into the cerebrospinal fluid of patients with neuroborreliosis: the role of CXCL10 and CXCL11. J Neuroimmunol 2005, 163:128-134.
45. Lahrtz F, Piali L, Nadal D, Pfister HW, Spanaus KS, Baggiolini M, Fontana A. Chemotactic activity on mononuclear cells in the cerebrospinal fluid of patients with viral meningitis is mediated by interferon-gamma inducible protein-10 and monocyte chemotactic protein-1. Eur J Immunol 1997, 27:2484-2489.
46. Kolb SA, Sporer B, Lahrtz F, Koedel U, Pfister HW, Fontana A. Identification of a T cell chemotactic factor in the cerebrospinal fluid of HIV-1-infected individuals as interferon-gamma inducible protein 10. J Neuroimmunol 1999, 93:172-181.
47. Cinque P, Bestetti A, Marenzi R, Sala S, Gisslen M, Hagberg L, Price RW. Cerebrospinal fluid interferon-gamma-inducible protein 10 (IP-10, CXCL10) in HIV-1 infection. J Neuroimmunol 2005, 168:154-163.
48. Wesselingh SL, Power C, Glass JD, Tyor WR, McArthur JC, Farber JM, Griffin JW, Griffin DE. Intracerebral cytokine messenger RNA expression in acquired immunodeficiency syndrome dementia. Ann Neurol 1993, 33:576-582.
49. Sørensen TL, Tani M, Jensen J, Pierce V, Lucchinetti C, Folcik VA, Qin S, Rottman J, Sellebjerg F, Strieter RM, Frederiksen JL, Ransohoff RM. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999, 103:807-815.
50. Sørensen TL, Roed H, Sellebjerg F. Optic neuritis: chemokine receptor CXCR3 and its ligands. Br J Ophthalmol 2004, 88:1146-1148.
51. Sørensen TL, Trebst C, Kivisäkk P, Klaege KL, Majmudar A, Ravid R, Lassmann H, Olsen DB, Strieter RM, Ransohoff RM, Sellebjerg F. Multiple sclerosis: a study of CXCL10 and CXCR3 co-localization in the inflamed central nervous system. J Neuroimmunol 2002, 127:59-68.
52. Xia MQ, Bacskai BJ, Knowles RB, Qin SX, Hyman BT. Expression of the chemokine receptor CXCR3 on neurons and the elevated expression of its ligand IP-10 in reactive astrocytes: in vitro ERK1/2 activation and role in Alzheimer's disease. J Neuroimmunol 2000, 108:227-235.
53. Riemer C, Schultz J, Burwinkel M, Schwarz A, Mok SWF, Gültner S, Bamme T, Norley S, van Landeghem F, Lu B, Gerard C, Baier M. Accelerated prion replication in, but prolonged survival times of, prion-infected CXCR3-/-mice. J Virol 2008, 82:12464-12471.
54. Kipp M, Clarner T, Dang J, Copray S, Beyer C. The cuprizone animal model: new insights into an old story. Acta Neuropathol 2009, 118:723-736.
55. Torkildsen O, Brunborg LA, Myhr K-M, Bø L. The cuprizone model for demyelination. Acta Neurol Scand Suppl C 2008, 188:72-76.
56. McMahon EJ, Suzuki K, Matsushima GK. Peripheral macrophage recruitment in cuprizone-induced CNS demyelination despite an intact blood-brain barrier. J Neuroimmunol 2002, 130:32-45.
57. Carlton WW. Studies on the induction of hydrocephalus and spongy degeneration by cuprizone feeding and attempts to antidote the toxicity. Life Sci 1967, 6:11-19.
58. Carlton WW. Response of mice to the chelating agents sodium diethyldithiocarbamate, α-benzoinoxime, and biscyclohexanone oxaldihydrazone. Toxicol Appl Pharm 1966, 8:512-521.
59. Remington LT, Babcock AA, Zehntner SP, Owens T. Microglial recruitment, activation, and proliferation in response to primary demyelination. Am J Pathol 2007, 170:1713-1724.
60. Koutsoudaki PN, Skripuletz T, Gudi V, Moharregh-Khiabani D, Hildebrandt H, Trebst C, Stangel M. Demyelination of the hippocampus is prominent in the cuprizone model. Neurosci Lett 2009, 451:83-88.
61. Gudi V, Moharregh-Khiabani D, Skripuletz T, Koutsoudaki PN, Kotsiari A, Skuljec J, Trebst C, Stangel M. Regional differences between grey and white matter in cuprizone induced demyelination. Brain Res 2009, 1283:127-138.
62. Skripuletz T, Lindner M, Kotsiari A, Garde N, Fokuhl J, Linsmeier F, Trebst C, Stangel M. Cortical demyelination is prominent in the murine cuprizone model and is strain-dependent. Am J Pathol 2008, 172:1053-1061.
63. Skripuletz T, Hackstette D, Bauer K, Gudi V, Pul R, Voss E, Berger K, Kipp M, Baumgärtner W, Stangel M. Astrocytes regulate myelin clearance through recruitment of microglia during cuprizone-induced demyelination. Brain 2013, 136:147-167.
64. Boztug K, Carson MJ, Pham-Mitchell N, Asensio VC, DeMartino J, Campbell IL. Leukocyte infiltration, but not neurodegeneration, in the CNS of transgenic mice with astrocyte production of the CXC chemokine ligand 10. J Immunol 2002, 169:1505-1515.
65. Mayo L, Quintana FJ, Weiner HL. The innate immune system in demyelinating disease. Immunol Rev 2012, 248:170-187.
66. Tirotta E, Ransohoff RM, Lane TE. CXCR2 signaling protects oligodendrocyte progenitor cells from IFN-γ/CXCL10-mediated apoptosis. Glia 2011, 59:1518-1528.
67. Omari KM, John GR, Sealfon SC, Raine CS. CXC chemokine receptors on human oligodendrocytes: implications for multiple sclerosis. Brain 2005, 128:1003-1015.
68. Islam MS, Tatsumi K, Okuda H, Shiosaka S, Wanaka A. Olig2-expressing progenitor cells preferentially differentiate into oligodendrocytes in cuprizone-induced demyelinated lesions. Neurochem Int 2009, 54:192-198.
69. Franklin RJM, Kotter MR. The biology of CNS remyelination: the key to therapeutic advances. J Neurol 2008, 255(Suppl 1):19-25.